Not Signed In -
Ezetimibe |
Zetia |
Clinical Trial: A Study to Evaluate Ezetimibe in Korean Patients with Primary Hypercholesterolemia
This study is no longer recruiting patients.
|
Purpose
Patients undergo 4-week placebo lead-in and diet period, and 12-week treatment period. Clinical efficacy and safety is evaluated at weeks 4, 8 and 12. This study takes approximately 18 weeks for an individual patient to complete including post-visit at week 14.
| Condition | Intervention | Phase |
|---|---|---|
| Hypercholerolemia | Drug: MK0653; ezetimibe | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction with Another Drug in Korean Patients with Primary Hypercholesterolemia
Further Study Details:
Study start: December 2002
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Korean males or females at least 18 years of age with hypercholesterolemia
Location Information
Korea, Republic of
MSD Korea Ltd., Seoul, 121-705, Korea, Republic of
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_065
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157911
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157911
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
